1258305-26-8

Basic information

• Product Name: 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one
• Synonyms: 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one
• CAS NO: 1258305-26-8
• Molecular Weight: 502.638
• Mol File: 1258305-26-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one(1258305-26-8)
• EPA Substance Registry System: 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one(1258305-26-8)

Safety Data

• Hazardous Substances Data: 1258305-26-8(Hazardous Substances Data)

Upstream product

• 21655-48-1 cis-2,6-dimethylpiperazine 
• 139756-21-1 5-(2-ethoxy)-phenyl-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one 
• 147539-61-5 (3r,5s)-rel-1,2,6-trimethylpiperazine 
• 139756-22-2 5-(5-Chlorosulphonyl-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
• 1152111-15-3 tert-butyl cis-3,4,5-trimethylpiperazine-1-carboxylate 
• 129779-30-2 (3S,5R)-3,5-dimethylpiperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1258305-28-0 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one citrate 

Relevant articles and documents

COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF

The present invention discloses a compound of formula (I) and citrate thereof as type 5 phosphodiesterase inhibitor, a preparation method thereof, and a pharmaceutical composition including the compound of formula (I) and citrate thereof. The experimental results of the present invention prove that the compound of formula (I) and citrate thereof can inhibit activity of type 5 phosphodiesterase, and can be used for treating erectile dysfunction, inhibiting platelet aggregation and treating thrombosis, decreasing pulmonary hypertension and treating cardiovascular diseases, treating asthma and treating diabetes gastroparesis.